InnovivavsJohnson & Johnson

INVA and JNJ stock compared: price, dividend, valuation and results, from SEC filings.

Innoviva (INVA) has a market value of $1.4B and Johnson & Johnson (JNJ) $643B. Over the last year, with dividends, INVA moved -16.0% and JNJ +36.4%. The P/E is 7.0 for INVA and 40.0 for JNJ. Dividend yield: INVA none, JNJ 1.98%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    INVA$1.4B

    JNJ$643B

    JNJ is 473 times INVA

  • Revenue, 12 months

    INVA$438M

    JNJ$99.3B

    JNJ is 227 times INVA

  • Net income, 12 months

    INVA$193M

    JNJ$16.1B

    JNJ is 83 times INVA

  • Operating margin

    INVA38.8%

    JNJ–

  • ROIC

    INVA9.5%

    JNJ12.4%

    2.9 points apart

  • P/E

    INVA7.0

    JNJ40.0

    JNJ is 5.7 times INVA

  • Dividend yield

    INVA0.0%

    JNJ2.0%

    2.0 points apart

  • 5-year return

    INVA+7.2%

    JNJ+88.9%

    81.7 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

INVA+7.2%

JNJ+88.9%

10015020020222023202420252026
Returns by period
PeriodINVAWith dividendsJNJWith dividends
1 year since November 18, 2025-16.0%Price -16.0%+36.4%Price +33.4%
3 years since November 17, 2023+33.8%+10.2% a yearPrice +33.8%+94.0%+24.7% a yearPrice +78.2%
5 years since November 18, 2021+7.2%+1.4% a yearPrice +7.2%+88.9%+13.6% a yearPrice +64.3%
10 years since November 21, 2016+68.1%+5.3% a yearPrice +68.1%+202.4%+11.7% a yearPrice +132.1%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

INVAInnovivaJNJJohnson & Johnson

Valuation

INVAJNJ
Valuation
Price$18.36$266.87
Market value$1.4B$643B
Enterprise value (EV)$1.0B$671B
P/E7.040.0
P/E, 5-year median6.121.9
P/B1.27.9
EV/EBIT6.137.8
Free cash flow yield13.4%3.2%

Results and growth

INVAJNJ
Results and growth
Revenue, 12 months$438M$99.3B
Net income, 12 months$193M$16.1B
Free cash flow, 12 months$183M$20.6B
Earnings per share, 12 months$2.61$6.59
Revenue growth, year on year14.7%6.1%
Revenue growth a year, past+4.1%over 5 years+2.7%over 5 years
EPS growth a year, past+10.3%over 5 years+14.9%over 5 years

Margins and returns on capital

INVAJNJ
Margins and returns on capital
Gross margin74.5%67.6%
Operating margin38.8%–
Net margin44.1%16.2%
ROIC9.5%12.4%
ROE16.4%19.7%

Balance sheet

INVAJNJ
Balance sheet
Cash$581M$17.2B
Total debt$270M$44.7B
Net debt / EBITDA–1.1
Interest cover8.6×18.0×

Dividends and buybacks

INVAJNJ
Dividends and buybacks
Dividend yield–2.0%
Dividend per share, 12 months–$5.28
Dividend growth a year, past–+5.3%over 5 years
Buyback yield0.3%0.9%
Shareholder yield0.3%2.9%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: INVA or JNJ

Didn't find what you were looking for?

Ask us
Which is bigger, Innoviva or Johnson & Johnson?

By market value, Johnson & Johnson ($643B) is about 472.8 times Innoviva ($1.4B), at today's prices.

How did INVA and JNJ stock do over the last 10 years?

Since November 21, 2016, INVA's price moved +68.1% and JNJ's +132.1%. With dividends: INVA +68.1% (+5.3% a year), JNJ +202.4% (+11.7% a year). Past returns do not predict future ones.

Which pays the higher dividend, INVA or JNJ?

The dividend yield at today's price is none for Innoviva and 1.98% for Johnson & Johnson. Over the last twelve months they paid – and $5.28 per share.

What is the P/E of INVA and JNJ?

At today's price, the P/E is 7.0 for INVA and 40.0 for JNJ. The median of the last five years was 6.1 and 21.9, which shows where each stands against its own past.

Which has the higher profit margins, Innoviva or Johnson & Johnson?

Over the last twelve months, the net margin was 44.1% for Innoviva and 16.2% for Johnson & Johnson, and the operating margin 38.8% and –. Revenue was $438M and $99.3B.

Which is the better investment, Innoviva or Johnson & Johnson?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.